Quadratus Lumborum Block by Paraspinous Sagittal Shift Approach With Different Concentrations Of Bupivacaine in Hip Surgeries

Comparison Of The Analgesic Efficacy Of Quadratus Lumborum Block By Paraspinous Sagittal Shift Approach With Different Concentrations Of Bupivacaine in Hip Surgeries

The aim of this study is to evaluate the optimum concentration of bupivacaine in Paraspinous Sagittal Shift Approach for Quadratus Lumborum Block in hip Surgeries

Study Overview

• Status: Unknown
• Conditions: Hip Surgeries
• Intervention / Treatment: Other: quadratus lumborum block by paraspinous sagittal shift approach

Detailed Description

With the patient in the lateral decubitus and the block side independent, a curvilinear ultrasound transducer (2-5 MHz) will be directed caudally in a sagittal plane 3-4 cm lateral to the lumbar spinous process of L4, which is almost opposite to the iliac crest, producing a longitudinal scan of the lumbar paravertebral region; and thus identifying the transverse processes of L3 and L4, with PM muscle in-between and erector spinae muscle posteriorly.

The probe is shifted slowly to the lateral side until the transverse processes disappear and the QL muscle is evident in its long axis attached caudally to the iliac crest with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, QL, and PM muscles respectively. After subcutaneous local infiltration with lidocaine at the cephalic end of the probe, the block needle is advanced in a cephalo-caudal direction, through the erector spinae and QL muscles, until it pierces the epimysium of the QL. LA is injected anterior to the QL muscle, observing its spread in a caudal direction towards the iliac crest between the QL and psoas muscles

• Study Type: Interventional
• Enrollment (Anticipated): 5
• Phase: Phase 4

Contacts and Locations

Study Locations

• Egypt
  • Benisuef
    • Banī Suwayf, Benisuef, Egypt, 62511
      • Recruiting
      • Benisuef univercity

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• ASA I and II undergoing hip surgery.

Exclusion Criteria:

• Contraindications for regional blocks (eg. Patient refusal Infection at the injection site, coagulopathy) allergic reaction to drugs. opium addiction, any drug or substance abuse

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Group 0.25% bupivacaine; 30 ml 0.25% bupivacaine	Other: quadratus lumborum block by paraspinous sagittal shift approach; quadratus lumborum block by paraspinous sagittal shift approach
Active Comparator: Group 0.375% bupivacaine; 0.375% bupivacaine	Other: quadratus lumborum block by paraspinous sagittal shift approach; quadratus lumborum block by paraspinous sagittal shift approach

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
time to first request of analgesics	Postoperative time to first request of analgesics (hours)	Postoperative 24 hours

Collaborators and Investigators

• Sponsor: Beni-Suef University

Study record dates

Study Major Dates

• Study Start (Anticipated): November 20, 2020
• Primary Completion (Anticipated): December 30, 2020
• Study Completion (Anticipated): December 30, 2020

Study Registration Dates

• First Submitted: September 30, 2020
• First Submitted That Met QC Criteria: November 9, 2020
• First Posted (Actual): November 13, 2020

Study Record Updates

• Last Update Posted (Actual): November 20, 2020
• Last Update Submitted That Met QC Criteria: November 19, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: FMBSUREC/01092020/Abd El Badei

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No